Methods for treating cancer using subcutaneous dosing of mosunetuzumab in combination with polatuzumab vedotin
US-2026078198-A1 · Mar 19, 2026 · US
This page is not indexed by search engines while we improve data quality.
Oki Yasuhiro patents
Oki Yasuhiro is listed as an inventor on 7 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Oki Yasuhiro |
| Total patents | 7 |
| First publication | Dec 29, 2022 |
| Latest publication | Mar 19, 2026 |
Notable patents
Publications ranked by popularity score, then publication date.
Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
US-2026055204-A1 · Feb 26, 2026 · US
Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
US-2025250353-A1 · Aug 7, 2025 · US
Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
US-12291575-B2 · May 6, 2025 · US
Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion
US-2023190784-A1 · Jun 22, 2023 · US
Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion
US-11571440-B2 · Feb 7, 2023 · US
Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
US-2022411528-A1 · Dec 29, 2022 · US
Recent patents
Latest publications not already listed above.
No data yet.
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Genentech Inc | 5 |
| Jazz Pharmaceuticals Ireland Ltd | 2 |
| Hoffmann La Roche | 1 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| C07K16/2866 | 5 |
| A61K2039/545 | 5 |
| A61K2039/507 | 5 |
| A61P35/00 | 5 |
| C07K2317/31 | 5 |